Leadership & Pay ·
Following its Annual General Meeting on September 4, 2026, Evogene Ltd. reported that dissident shareholders L.I.A.…
EVGNEvogene Ltd.
Following its Annual General Meeting on September 4, 2026, Evogene Ltd. reported that dissident shareholders L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. challenged the voting results and issued notice of intent to launch a special tender offer under Israeli law. Concurrently, directors Yoshinori Oikawa and Dr. Yael Margolin resigned from the board on September 9, 2026, with no stated disagreements regarding company operations or policies. The Company is currently engaging in discussions with these shareholders to resolve the disputes. Evogene Ltd. operates in the biotechnology industry, focusing on drug discovery and development using its proprietary platforms.